Arpeggio Biosciences
Edit

Arpeggio Biosciences

http://www.arpeggiobio.com/
Last activity: 29.05.2024
Active
Categories: Artificial IntelligenceBioTechDevelopmentDrugInvestmentLearnMedtechNetworksPlatformTechnology
Our technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development.

We are comprised of a talented, diversely-skilled team, working together towards the mission of helping bring new therapies to patients with epigenetically-driven diseases.
Followers
184
Mentions
5
Location: United States, Colorado, Boulder
Employees: 1-10
Total raised: $20.2M
Founded date: 2017

Investors 3

Funding Rounds 2

DateSeriesAmountInvestors
07.09.2022Series A$17M-
17.01.2020Seed$3.2M-

Mentions in press and media 5

DateTitleDescription
29.05.2024Slone Partners Places Kevin Eastwood as Chief Business Officer at Arpeggio BiosciencesSlone Partners Places Kevin Eastwood as Chief Business Officer at Arpeggio Biosciences Industry veteran brings more than 25 years of experience in senior leadership roles SOUTH RIDING, Va., May 29, 2024 /PRNewswire-PRWeb/ -- Slone Partners,...
05.05.2024Business | Boulder life-sciences leaders: Pfizer’s exit means opportunityLefkoff listed “six identifiable spinoffs” since Pfizer bought Array, four of which are publicly traded companies. They’re all doing very well. “That’s what you want to see in an ecosystem like ours,” he said. “Nobody leaves, nobody’s freak...
07.09.2022Arpeggio Biosciences Raises $17M in Series A FundingArpeggio Biosciences, a Boulder, CO-based preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, raised $17m in Series A funding. The round, which follows a $3.2m seed round completed in 2020, wa...
07.09.2022Arpeggio Biosciences rakes in $17M to measure the transcriptomeHow can drug developers design therapies around cellular networks rather than a single target? That is the question Arpeggio Biosciences is seeking to answer — and with a new influx of funds. The Boulder, Colorado-based startup announced th...
15.01.2020Arpeggio Bio Secures USD 3.2M in Seed FundingArpeggio Bio , a Boulder, Colo.-based preclinical company whose technology provides a mechanistic understanding of how drugs work, closed a $3.2m seed financing round. Backers included Khosla Ventures, FundersClub, Fifty Years, TechU, and Y...

Reviews 0

Sign up to leave a review

Sign up Log In